Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies [PDF]
, 2020 The treatment of patients affected by non-small cell lung cancer (NSCLC) has been revolutionised by the discovery of druggable mutations. ROS1 (c-ros oncogene) is one gene with druggable mutations in NSCLC.
Ferrari, Katia +3 more
core +4 more sources
BIOANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF ENTRECTINIB IN RAT PLASMA BY LIQUID CHROMATOGRAPHY–TANDEM MASS SPECTROMETRY [PDF]
, 2020 Objective: The objective of the study was to develop and validate the bioanalytical liquid chromatography–mass spectrometry (LCMS/MS) method for the estimation of entrectinib in bulk and pharmaceutical drugs in rat plasma.
KE, PRAVALLIKA +2 more
core +1 more source
Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report
European Thyroid Journal, 2023 Background: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive solid tumors. ATC is frequently diagnosed at advanced stages with unresectable disease and palliative care is often indicated.
Inês Damásio +7 more
doaj +1 more source
Identification of inhibitors of an unconventional Trypanosoma brucei kinetochore kinase [PDF]
, 2019 The discovery of 20 unconventional kinetochore proteins in Trypanosoma brucei has opened a new and interesting area of evolutionary research to study a biological process previously thought to be highly conserved in all eukaryotes.
De Rycker, Manu +5 more
core +3 more sources
Precision Medical Sciences, EarlyView.Abstract ROS1‐rearranged lung adenocarcinoma is a rare subset of non‐small‐cell lung cancer, typically occurring in young never‐smokers. Its occurrence in very young men with a fluid‐dominant presentation is unusual and may lead to diagnostic pitfalls.
Thanh Thao Nguyen +4 more
wiley +1 more source
MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC
Thoracic Cancer, 2022 Background ROS1 tyrosine kinase inhibitors (TKIs) have demonstrated significant clinical benefit for ROS1+ NSCLC patients. However, TKI resistance inevitably develops through ROS1 kinase domain (KD) modification or another kinase driving bypass signaling.
Logan C. Tyler +13 more
doaj +1 more source
Frontiers in Oncology, 2023 Background: Neurotrophic tyrosine receptor kinase (NTRK) gene-fusion targeted molecules revolutionized the paradigm of treatment of a limited subgroup of cancers of various histologies.
Emanuela Palmerini +17 more
doaj +1 more source
A preexisting rare PIK3CA e545k subpopulation confers clinical resistance to MEK plus CDK4/6 inhibition in NRAS melanoma and is dependent on S6K1 signaling [PDF]
, 2018 Combined MEK and CDK4/6 inhibition (MEKi + CDK4i) has shown promising clinical outcomes in patients with NRAS- mutant melanoma. Here, we interrogated longitudinal biopsies from a patient who initially responded to MEKi + CDK4i therapy but subsequently ...
Amaria, Rodabe N. +20 more
core +1 more source
Asia-Pacific Journal of Clinical Oncology, EarlyView.Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown +7 more
wiley +1 more source
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC [PDF]
, 2022 (NSCLCs). Several tyrosine kinase inhibitors (TKIs) have shown high efficacy in patients whose tumors harbour a ROS1 fusion. However, the limited availability of preclinical models of ROS1-positive NSCLC hinders the discovery of new drugs and the ...
Altimari, Annalisa +17 more
core +2 more sources